Development and Validation of a Model to Predict Ureteral Stent Placement Following Ureteroscopy: Results From a Statewide Collaborative - 10/08/23

on behalf of the Michigan Urological Surgery Improvement Collaborative
ABSTRACT |
Objective |
To develop and validate a model to predict whether patients undergoing ureteroscopy (URS) will receive a stent.
Methods |
Using registry data obtained from the Michigan Urological Surgery Improvement Collaborative Reducing Operative Complications from Kidney Stones initiative, we identified patients undergoing URS from 2016 to 2020. We used patients’ age, sex, body mass index, size and location of the largest stone, current stent in place, history of any kidney stone procedure, procedure type, and acuity to fit a multivariable logistic regression model to a derivation cohort consisting of a random two-thirds of episodes. Model discrimination and calibration were evaluated in the validation cohort. A sensitivity analysis examined urologist variation using generalized mixed-effect models.
Results |
We identified 15,048 URS procedures, of which 11,471 (76%) had ureteral stents placed. Older age, male sex, larger stone size, the largest stone being in the ureteropelvic junction, no prior stone surgery, no stent in place, a planned procedure type of laser lithotripsy, and urgent procedure were associated with a higher risk of stent placement. The model achieved an area under the receiver operating characteristic curve of 0.69 (95% CI 0.67, 0.71). Incorporating urologist-level variation improved the area under the receiver operating characteristic curve to 0.83 (95% CI 0.82, 0.84).
Conclusion |
Using a large clinical registry, we developed a multivariable regression model to predict ureteral stent placement following URS. Though well-calibrated, the model had modest discrimination due to heterogeneity in practice patterns in stent placement across urologists.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure: CAD is a consultant for Boston Scientific and Cook. KRG is a consultant for Boston Scientific, Olympus, Karl Sotrz, Ambu, and Coloplast and receives grant funding from Coloplast, Boston Scientific, and PCORI. KS serves on a scientific advisory board for Flatiron Health and receives grant funding from Teva Pharmaceuticals for unrelated work. |
|
| Funding Support: This work was supported by Blue Cross Blue Shield of Michigan. The sponsor played no direct role in the study. |
Vol 177
P. 34-40 - juillet 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
